AstraZeneca

AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Company Growth (employees)
Type
Public
HQ
Cambridge, GB
Founded
1999
Size (employees)
59,700 (est)-2%
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB

Key People at AstraZeneca

Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Marc Dunoyer

Marc Dunoyer

CFO
Herren Wu

Herren Wu

CTO
Bahija Jallal

Bahija Jallal

Executive Vice President
Menelas Pangalos

Menelas Pangalos

Executive Vice President
Mark Mallon

Mark Mallon

Executive Vice President
Jeff Pott

Jeff Pott

General Counsel
Katarina Ageborg

Katarina Ageborg

Chief Compliance Officer
Caroline Hempstead

Caroline Hempstead

Executive Vice President, Human Resources and Corporate Affairs (interim)
Pam Cheng

Pam Cheng

Executive Vice-President
Fiona Cicconi

Fiona Cicconi

Executive Vice-President, Human Resources

AstraZeneca Office Locations

AstraZeneca has offices in Cambridge, London, Bangalore, Hong Kong and in 166 other locations
Wedel, DE
Wedel, Tinsdaler Weg 183
Wilmington, US
1800 Concord Pike, P.O. Box 15437
Osaka, JP
Grand Front Osaka Tower B, 3 1, Ofuka Cho, Kita Ku
Shanghai, CN
43/F Citic Square, 1168 Nan Jing Xi Road
Hong Kong, HK
18/F, Shui On Centre, 6 8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
Show all (171)

AstraZeneca Data and Metrics

AstraZeneca Financial Metrics

AstraZeneca's revenue was reported to be $21.3 b in FY, 2016 which is a 10% decrease from the previous period.
USD

Revenue (FY, 2016)

21.3 b

Revenue growth (FY, 2015 - FY, 2016), %

(10%)

Gross profit (FY, 2016)

17.2 b

Gross profit margin (FY, 2016), %

81%

Net income (FY, 2016)

3.4 b

Market capitalization (24-Jul-2017)

85.7 b

Closing share price (24-Jul-2017)

34.1

Cash (31-Dec-2016)

3.9 b
AstraZeneca's current market capitalization is $85.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

25.7 b26.1 b23.6 b21.3 b

Revenue growth, %

1%(9%)(10%)

Cost of goods sold

5.3 b5.8 b4.6 b4.1 b

Gross profit

20.5 b20.3 b19 b17.2 b

Gross profit Margin, %

80%78%80%81%

Sales and marketing expense

306 m324 m339 m326 m

R&D expense

4.8 b5.6 b6 b5.9 b

General and administrative expense

12.2 b13 b11.1 b9.4 b

Operating expense total

17.3 b18.9 b17.4 b15.6 b

Depreciation and amortization

4.6 b3.3 b2.9 b

Interest expense

(495 m)(963 m)(1.1 b)1.4 b

Interest income

50 m78 m46 m67 m

Pre tax profit

2.1 b1.2 b3.1 b3.6 b

Income tax expense

(696 m)11 m243 m146 m

Net Income

2.6 b1.2 b2.8 b3.4 b
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash

6.1 b4.7 b4.6 b3.9 b

Accounts Receivable

3.6 b3.5 b3.4 b2 b

Current Assets

13.2 b12.2 b11.7 b10.1 b

PP&E

6.4 b7 b7.2 b8 b

Goodwill

17.1 b24.1 b25.5 b30.4 b

Total Assets

36.8 b43.3 b44.5 b48.4 b

Accounts Payable

1.6 b2.6 b2.6 b2.3 b

Current Liabilities

10.6 b12.8 b11 b11.8 b

Total Liabilities

21.5 b28.8 b30.8 b36.9 b

Retained Earnings

1.7 b(1.7 b)(488.1 m)(120 m)

Total Equity

15.3 b14.5 b13.7 b11.5 b

Financial Leverage

2.4 x3 x3.3 x4.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

7.4 b7.1 b3.3 b4.1 b

Cash From Financing Activities

(2 b)(2 b)649.3 m1.7 b

Income Taxes Paid

(457.7 m)(8.1 m)(179.7 m)(113.1 m)
Y, 2016

Financial Leverage

4.2 x

AstraZeneca Operating Metrics

Y, 2013Y, 2014Y, 2015Y, 2016

Phase I Trials

33244441

Phase II Trials

27113336

Countries

100100100100

Projects in R&D Pipeline

99133146132

Phase III Trials

19113527

NME in Late-stage Development

7131512

Young Health Programme Members

1.4 m1.6 m

Healthcare Workers

2.6 k3 k

Health Facilities Activated

250403

Drugs Approved by FDA

1

    AstraZeneca Market Value History

    AstraZeneca Revenue Breakdown

    AstraZeneca Median Salaries

    Source: 105 public H-1B filings from AstraZeneca

    AstraZeneca Online and Social Media Presence

    AstraZeneca News and Updates

    AstraZeneca Company Life and Culture

    You may also be interested in